Phase 1 study of the folic acid (FA) and tubulysin B hydrazide (TubBH) small molecule drug conjugate (SMDC) EC1456 in patients (pts) with advanced cancers (CA).
Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 2551-2551
QUADRA: A phase 2, open-label, single-arm study to evaluate niraparib in patients (pts) with relapsed ovarian cancer (ROC) who have received ≥3 prior chemotherapy regimens.
Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 5514-5514